Clinical Trial

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2024 (before its estimated June 27, 2025 completion). Its status may not reflect the trial's current state.
Summary
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-01-26; most recent amendment 2024-10-17.
Status change: Not Yet Recruiting → Recruiting 2024-10-17
Trial Details
NCT Number NCT05224960
Lead Sponsor Beijing 302 Hospital
Collaborators: Chinese PLA General Hospital, Shanghai Changzheng Hospital, LanZhou University, Jin Yin-tan Hospital, Hainan General Hospital, Vcanbio Cell and Gene Engineering Corp., Ltd., Third Affiliated Hospital, Sun Yat-Sen University, Xinjiang Kashi Area Number 1 Hospital
Conditions Decompensated Cirrhosis
Enrollment 140 participants
Start Date 2024-06-27
Primary Completion 2025-06-27 (estimated)
Study Completion 2027-06-20 (estimated)
Updated on ClinicalTrials.gov 2024-10-18